Blue ribbon panel, Stanford release Nezhat findings
Stanford plan shared nationwide as a model for response to bioterrorism threatsl
Pill-sized camera tested at Stanford offers unique glimpse inside small intestines
Vice president of human resources named
'Advanced Access' program at two primary-care clinics cut waiting out of doctor visits
Patient Representative Associates play key role in Emergency Department
Anthrax threat slows DEA renewal process
SHC, LPCH employees donate PTO to Sept. 11 charity
The
accomplishments of your colleagues and associates
are making a significant impact. Detailed news releases
and/or source material are available at the
Stanford University Medical Center
Office of News and Public Affairs,
701 Welch Road, Suite 2207, Palo Alto, CA 94304;
phone (650) 723-6911;
and on the Internet at
(http://www-med.stanford.edu/MedCenter/Communications/)
ASTHMA GENE - A novel gene family that appears critical to the development of asthma in mice has been identified and reported in the December issue of Nature Immunology by Stanford researchers led by pediatrics professor Rosemarie DeKruyff. The newly discovered link between the gene family called Tim and the hepatitis A virus may help explain why infection with the virus seems to protect against asthma and provide a clue to why asthma rates are increasing in regions where hepatitis A infection is dropping. Other research participants include professors Gregory Barsh and Dale Umetsu; and Jennifer McIntire, Omid Akbari and undergraduate student Sarah Umetsu.
LOW-DOSE THERAPY - A new treatment for a type of pediatric brain tumor is being tested by physicians at Lucile Packard Children's Hospital using less radiation and more chemotherapy than conventional therapy. The study led by Paul Fisher, an assistant professor of neurology, pediatrics and neurosurgery, is part of a nationwide clinical trial of a special low-dose therapy, aimed at preventing damage to developing brains while treating medulloblastoma, the most common type of brain tumor in children. The trial is designed to test whether 1,800 cGy - combined with one extra round of chemotherapy - will be enough to conquer the tumor without damage to the brain.
EVOLUTIONARY MECHANISMS - Stanford researchers proposed in the Dec. 20 issue of Nature that a small fish called the three-spine stickleback along with the gene-linkage map of the fish's chromosomes may be a means of applying what scientists know to be true in a lab to systems in the natural world. The researchers include developmental biology professor David Kingsley, HHMI research associate Catherine Peichel and others. Kingsley said the initial results suggest that these fish can now be used for detailed genetic studies of the mechanisms that control vertebrate evolution.
